Enliven Therapeutics, Inc.ELVN

$45.10+0.24 (+0.53%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$3B

Mid-cap

+809%

2020 — today

10-Year Price

-37%

2020 — today

52-Week Range

$15.14$48.11

Current $45.10· 91%

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Valuation in context

P/E ratio

-27.5

N/A

Not meaningful — company is unprofitable

P/B ratio

6.2

Near historic high

Near historic highs — last 10 years

FCF Yield

-2.3%

Near historic high

Near historic highs — last 10 years

Free · No credit card needed

Get alerted when ELVN is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.